AI Science Tracker
EN

Morphological heterogeneity description enabled early and parallel non-invasive prediction of T-cell proliferation inhibitory potency and growth rate for facilitating donor selection of human mesenchymal stem cells.

Department of Basic Medicinal Sciences, Graduate School of Pharmaceutical Sciences, Nagoya University, Tokai National Higher Education and Research System, Furocho, Chikusa-ku, Nagoya, Aichi, 464-8601, Japan · 30 Jan 2022 · medicine

Discovery

Morphological heterogeneity description enabled early and parallel non-invasive prediction of T-cell proliferation inhibitory potency and growth rate for facilitating donor selection of human mesenchymal stem cells.

Source check: Source checked. Not independent scientific confirmation.

Finding / tested result: The primary article uses image-derived morphological profiles and machine learning to predict mesenchymal-stem-cell T-cell inhibitory potency and growth rate within four days, supporting donor/lot selection.

Technology: Models use 32 time-course morphology parameters to classify risky lots and predict growth rate.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Models use 32 time-course morphology parameters to classify risky lots and predict growth rate.
Limitation / still unknown
Results are limited to the reported models, cohorts, datasets or experiments; broader generalization and clinical or operational benefit were not established.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://link.springer.com/article/10.1186/s41232-021-00192-5

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.